Opportunity Information: Apply for PAR 14 230
Apply for PAR 14 230
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.399 Cancer Control.
- This funding opportunity was created on May 19, 2014 and posted on May 19, 2014.
- Applicants must submit their applications by Apr 17, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,500,000.00 to eligible and selected applicants.
- Eligible applicants include: Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments County governments Independent school districts Public housing authorities/Indian housing authorities State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Special district governments Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-14-230, titled "Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33)," was designed to move the field toward better, more tailored ways to help people with schizophrenia stop smoking. The central idea is that standard smoking cessation approaches often do not work as well in this population, so the FOA focused on developing and running early-stage, targeted intervention studies that are specifically built for the clinical and practical realities of schizophrenia. In addition to smokers with schizophrenia in general, the announcement explicitly highlights interest in individuals who also have co-occurring alcohol use disorders and/or other substance use disorders, reflecting how commonly these conditions overlap and how they can complicate quitting.
This FOA used the NIH R21/R33 phased innovation mechanism. In practical terms, that structure supports a stepwise research plan: an initial exploratory phase (R21) to generate key preliminary data and refine an approach, followed by a second phase (R33) intended for more advanced preliminary testing once predefined milestones are met. The emphasis is on de-risking and shaping promising cessation strategies before they are ready for large, definitive clinical trials. Because it is an exploratory-to-developmental pathway, applicants were generally expected to propose clear, measurable go/no-go criteria, such as recruitment feasibility, adherence benchmarks, safety and tolerability signals, acceptability to patients and providers, and early indicators of smoking reduction or abstinence that justify progressing to the next phase.
The scientific scope centers on smoking cessation treatments that are targeted to people with schizophrenia, which can include behavioral, pharmacological, or combined approaches, as well as adaptations that address cognitive symptoms, negative symptoms, medication interactions, high nicotine dependence, and common barriers like limited access to specialty care or challenges with treatment engagement. While the summary provided does not list specific required intervention types, the overall framing is about developing approaches that are intentionally tailored rather than simply borrowed from general-population cessation programs. The co-occurring substance use angle signals that integrated or coordinated approaches, or at least designs that account for substance use patterns, relapse risk, and treatment complexity, would fit well within the FOA's priorities.
Administratively, this was a discretionary grant program under the National Institutes of Health. The activity categories associated with the CFDA numbers indicate the cross-cutting relevance to mental health research (93.242), alcohol research (93.273), drug abuse and addiction research (93.279), and cancer control (93.399), which makes sense given that tobacco use drives major morbidity and mortality, including cancer risk, and is tightly linked to addiction and mental health outcomes. The FOA reported an estimated total funding amount of $3.5 million, and it did not require cost sharing or matching, which lowers a common barrier for applicants that may not have flexible institutional funds.
Eligibility was broad and included many domestic organization types such as nonprofits (both 501(c)(3) and certain non-501(c)(3) entities), small businesses, other for-profit organizations, city/county/state governments, school districts, public housing authorities, tribal governments and tribal organizations, and public and private institutions of higher education. The eligibility language also extended to a wide range of mission-specific institutions and community-based entities, including faith-based or community-based organizations, HBCUs, Hispanic-serving institutions, AANAPISI institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, regional organizations, and eligible federal agencies. Importantly, the FOA allowed non-U.S. entities to apply (foreign organizations and foreign institutions), allowed non-U.S. components of U.S. organizations to participate, and permitted foreign components as defined under NIH policy, which opens the door to international collaborations or studies in non-U.S. settings where appropriate and justifiable.
In terms of timing, the opportunity was posted and created on May 19, 2014. The original and current closing dates listed were April 17, 2017, and the archive date was May 18, 2017, meaning it is no longer open for new submissions under that specific announcement. For applicants at the time, the full details, requirements, and instructions were available through the NIH Grants Guide link provided in the announcement. The contact listed for access and technical issues was the NIH Office of Extramural Research webmaster (FBOWebmaster@OD.NIH.GOV), which is typical for resolving problems accessing the electronic announcement or links rather than for scientific programmatic questions.
Overall, PAR-14-230 can be summarized as an NIH effort to accelerate early-stage development and preliminary testing of smoking cessation interventions purpose-built for people with schizophrenia, with additional attention to those who also face alcohol and other substance use disorders. The goal was to produce credible, milestone-driven evidence that an intervention is feasible, acceptable, and promising enough to justify the next step toward larger-scale efficacy and effectiveness trials, ultimately aiming to reduce the disproportionate tobacco-related health burden in this high-risk population.
Frequently Asked Questions (FAQs)
What is PAR-14-230?
PAR-14-230 is an NIH funding opportunity announcement (FOA) titled "Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33)." It was designed to advance early-stage, targeted research on smoking cessation strategies specifically tailored for people with schizophrenia.
What problem was this FOA trying to address?
The FOA was built around the idea that standard smoking cessation approaches often do not work as well for people with schizophrenia. The opportunity aimed to support the development and preliminary testing of interventions that better match the clinical and practical realities of schizophrenia.
Who was the primary population of interest?
The primary population of interest was people with schizophrenia who smoke. The FOA emphasized tailoring cessation interventions to the specific needs and barriers commonly seen in this population.
Did the FOA specifically encourage studies involving co-occurring substance use?
Yes. In addition to smokers with schizophrenia in general, the FOA explicitly highlighted interest in individuals with co-occurring alcohol use disorders and/or other substance use disorders, reflecting how commonly these conditions overlap and how they can complicate quitting.
What grant mechanism did PAR-14-230 use?
PAR-14-230 used the NIH R21/R33 phased innovation mechanism. This supports a stepwise plan with an exploratory phase (R21) followed by a second, more advanced preliminary testing phase (R33) if predefined milestones are met.
How does the R21 phase differ from the R33 phase in this FOA?
Based on the description provided, the R21 phase was intended for exploratory work such as generating key preliminary data and refining the approach. The R33 phase was intended for more advanced preliminary testing once the project meets clear, predefined milestones established in the application.
What kinds of milestones or "go/no-go" criteria were expected?
Because this was an exploratory-to-developmental pathway, applicants were generally expected to propose clear, measurable go/no-go criteria. Examples mentioned include recruitment feasibility, adherence benchmarks, safety and tolerability signals, acceptability to patients and providers, and early indicators of smoking reduction or abstinence that would justify moving to the next phase.
What types of smoking cessation interventions were within scope?
The scientific scope centered on smoking cessation treatments targeted to people with schizophrenia. This could include behavioral approaches, pharmacological approaches, combined approaches, and adaptations designed for schizophrenia-specific barriers and clinical considerations.
Was the FOA limited to any single intervention type (for example, only medications or only counseling)?
No specific required intervention types were listed in the summary provided. The overall framing emphasized developing interventions that are intentionally tailored for schizophrenia, rather than simply borrowing general-population cessation programs without adaptation.
What schizophrenia-related factors did the FOA suggest interventions might need to address?
The FOA description noted that interventions could address factors such as cognitive symptoms, negative symptoms, medication interactions, high nicotine dependence, and common barriers like limited access to specialty care or challenges with treatment engagement.
How did co-occurring alcohol or other substance use fit into the research scope?
The FOA signaled that approaches integrating or coordinating care, or at least designs that account for substance use patterns, relapse risk, and treatment complexity, would align well with the stated priorities.
What was the overall goal of the R21/R33 structure for this topic?
The goal was to de-risk and shape promising smoking cessation strategies before they are ready for large, definitive clinical trials, using milestone-driven evidence to support progression from exploratory development to more advanced preliminary testing.
Which NIH research areas or program categories were associated with this opportunity?
The FOA was associated with CFDA areas reflecting its cross-cutting relevance to mental health research (93.242), alcohol research (93.273), drug abuse and addiction research (93.279), and cancer control (93.399).
Why was cancer control included among the associated areas?
As summarized in the provided information, tobacco use drives major morbidity and mortality, including cancer risk, and is closely linked to addiction and mental health outcomes. That linkage supports relevance to cancer control as well as addiction and mental health research.
How much total funding did the FOA estimate?
The FOA reported an estimated total funding amount of $3.5 million.
Did PAR-14-230 require cost sharing or matching funds?
No. The FOA did not require cost sharing or matching, which reduces a common barrier for applicants without flexible institutional funds.
What types of organizations were eligible to apply?
Eligibility was broad and included many domestic organization types such as nonprofits (both 501(c)(3) and certain non-501(c)(3) entities), small businesses, other for-profit organizations, city/county/state governments, school districts, public housing authorities, tribal governments and tribal organizations, and public and private institutions of higher education.
Did the FOA mention eligibility for community-based or mission-specific organizations?
Yes. The eligibility language included faith-based or community-based organizations and institutions such as HBCUs, Hispanic-serving institutions, AANAPISI institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, regional organizations, and eligible federal agencies.
Were non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA allowed non-U.S. entities to apply (foreign organizations and foreign institutions). It also allowed non-U.S. components of U.S. organizations to participate and permitted foreign components as defined under NIH policy.
Does the FOA being open to foreign entities imply international collaborations were allowed?
Yes. Based on the description, allowing foreign organizations and foreign components opens the door to international collaborations or studies in non-U.S. settings where appropriate and justifiable.
When was PAR-14-230 posted and when did it close?
The opportunity was posted and created on May 19, 2014. The listed closing date was April 17, 2017, and the archive date was May 18, 2017.
Is PAR-14-230 currently open for new submissions?
No. Based on the closing and archive dates provided, it is no longer open for new submissions under that specific announcement.
Where were applicants directed to find full requirements and instructions?
Applicants were directed to the NIH Grants Guide link provided in the announcement for full details, requirements, and instructions.
Who was listed as the contact for access or technical issues?
The contact listed for access and technical issues was the NIH Office of Extramural Research webmaster: FBOWebmaster@OD.NIH.GOV.
What kinds of issues was the listed contact intended to help with?
Based on the description, that contact is typical for resolving problems accessing the electronic announcement or links, rather than addressing scientific or programmatic questions.
What was the intended end result of projects funded under this FOA?
The intended end result was to produce credible, milestone-driven evidence that a tailored intervention is feasible, acceptable, and promising enough to justify the next step toward larger-scale efficacy and effectiveness trials, with the broader aim of reducing tobacco-related health burden in this high-risk population.
Browse more opportunities from the same category: Education Health
Next opportunity: Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33)
Previous opportunity: Office of Postsecondary Education (OPE) Fulbright Hays Doctoral Dissertation Research Abroad (DDRA) Fellowship Program CFDA Number 84.022A
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 230
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 230) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33) Apply for PAR 14 231 Funding Number: PAR 14 231 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) Apply for PAR 14 234 Funding Number: PAR 14 234 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01) Apply for PAR 14 240 Funding Number: PAR 14 240 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01) Apply for PAR 14 241 Funding Number: PAR 14 241 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Oncology Models Forum (U24) Apply for PAR 14 239 Funding Number: PAR 14 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Limited Competition Biospecimen Banks to Support NCI Clinical Trials Network (NCTN) (U24) Apply for RFA CA 14 501 Funding Number: RFA CA 14 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $11,750,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions Coordinating Center and Data Management Group (U01) Apply for RFA CA 14 011 Funding Number: RFA CA 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions (U01) Apply for RFA CA 14 010 Funding Number: RFA CA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovation Corps (I Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp) Apply for PAR 14 261 Funding Number: PAR 14 261 Agency: National Institutes of Health Category: Education Health Funding Amount: $25,000 |
| Outstanding Investigator Award (R35) Apply for PAR 14 267 Funding Number: PAR 14 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1) Apply for RFA DA 15 008 Funding Number: RFA DA 15 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Connectomes Related to Human Disease (U01) Apply for PAR 14 281 Funding Number: PAR 14 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 011 Funding Number: RFA DA 15 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21) Apply for RFA DA 15 012 Funding Number: RFA DA 15 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Innovative Research in Cancer Nanotechnology (IRCN) (U01) Apply for PAR 14 285 Funding Number: PAR 14 285 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs) (U54) Apply for RFA CA 14 013 Funding Number: RFA CA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College Attending Youth (U01) Apply for RFA DA 15 010 Funding Number: RFA DA 15 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Arts Based Approaches in Palliative Care for Symptom Management (R01) Apply for PAR 14 294 Funding Number: PAR 14 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 14 012 Funding Number: RFA CA 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| New Approaches to Synthetic Lethality for Mutant KRas Dependent Cancers (U01) Apply for PAR 14 314 Funding Number: PAR 14 314 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 230", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.